Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections

Archives of Disease in Childhood

Volumn 80, Issue 1, 1999, Pages 36-41

  Sas, Th C J ^a   De Muinck Keizer Schrama, S M P F ^a   Stijnen, Th ^h   Van Teunenbroek, A ^a   Hokken Koelega, A C S ^a   Waelkens, J J J ^b   Massa, G G ^c   Vulsma, Th ^d   Gerver, W J ^e   Reeser, H M ^h   Delemarre Van De Waal, H E ^f   Jansen, M ^g   Drop, S L S ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d EMMA CHILDREN S HOSPITAL   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h NONE

Author keywords

Final height; Growth; Growth hormone treatment; Turner's syndrome

Indexed keywords

ETHINYLESTRADIOL; GESTAGEN; GROWTH HORMONE; HUMAN GROWTH HORMONE; NORDIJECT 24; OXANDROLONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADOLESCENT; AGE; ARTICLE; BODY GROWTH; BODY HEIGHT; BONE AGE; CLINICAL ARTICLE; FEMALE; GROWTH HORMONE RELEASE; HORMONAL THERAPY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE; SCHOOL CHILD; SUBLINGUAL DRUG ADMINISTRATION; TURNER SYNDROME;

EID: 0033056160     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.80.1.36     Document Type: Article

References (42)

1. 1 Ranke MB, Pflüger H, Rosendahl W, et al. Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur J Pediatr 1983;141:81-8.
2. 2 Karlberg J, Albertsson-Wikland K, Naeraa RW, Rongen-Westerlaken C, Wit JM. Reference values for spontaneous growth in Turner girls and its use in estimating treatment effects. In: Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome. Amsterdam: Elsevier Science Publishers, 1993:83-92.
3. 3 Underwood LE. The social costs of being short: social perceptions and biases. Acta Pediatr Scand 1991;377(suppl):3-8.
4. 4 Stahnke N, Stubbe P, Attanasio A, Reinhardt D, Partsch CJ, Sippell WG. GH therapy alone or together with oxandrolone in 212 patients with Turner syndrome (TS): the German experience. In: Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome. Amsterdam: Elsevier Science Publishers, 1993:315-22.
5. 5 Chaussain JL, Gendrel C, Job B, Ducret JP. Optimizing of the dose of growth hormone in girls with Turner syndrome. In: Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome. Amsterdam: Elsevier Science Publishers, 1993:273-8.
6. 6 Teunenbroek van A, Muinck Keizer-Schrama de SMPF, Stijnen T, et al. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. J Clin Endocrinol Metab 1996;81:4013-21.
7. 7 Van den Broeck J, Massa GG, Attanasio A, et al. Final height after long-term growth hormone treatment in Turner syndrome. J Pediatr 1995;127:729-35.
8. 8 Nilsson KO, Albertsson-Wikland K, Alm J, et al. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab 1996;81:635-40.
9. 9 Haeusler G, Schmitt K, Blümel P, Plöchl E, Waldhör T, Frisch H. Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height. Acta Paediatr 1996;85:1408-14.
10. 10 Massa G, Otten BJ, Muinck Keizer-Schrama SMPF, et al. Treatment with two growth hormone regimens in girls with Turner syndrome: final height results. Horm Res 1995;43: 144-6.
11. 11 Taback SP, Collu R, Deal CL, et al. Does growth hormone supplementation affect adult height in Turner's syndrome? Lancet 1996;348:25-7.
12. 12 Rosenfeld RG, Frane J, Attie KM, et al. Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. J Pediatr 1992;121: 49-55.
13. 13 Rongen-Westerlaken C, Wit JM. Growth hormone therapy in Turner syndrome: the Dutch experience. In: Ranke MB, Rosenfeld R, eds. Turner syndrome: growth promoting therapies. Amsterdam: Elsevier Science Publishers, 1991: 225-9.
14. 14 Nienhuis HE, Rongen-Westerlaken C, Wit JM, et al. Results of long-term therapy with growth hormone in two dose regimens in Turner syndrome. Horm Res 1993;39(Suppl 2):31-6.
15. 15 Albertsson-Wikland K, Rosberg S. Analyses of 24-growth hormone profiles in children: relation to growth. J Clin Endocrinol Metab 1988;67:493-500.
16. 16 Ross JL, Long LM, Loriaux DL, Cutler GBJ. Growth hormone secretory dynamics in Turner syndrome. J Pediatr 1985;106:202-6.
17. 17 Ranke MB, Blum WF, Haug F, et al. Growth hormone, somatomedin levels and growth regulation in Turner's syndrome. Acta Endocrinol 1987;116:305-13.
18. 18 Lanes R, Brito S, Suniaga M, Moncada G, Borges M. Growth hormone secretion in pubertal age patients with Turner's syndrome. J Clin Endocrinol Metab 1990;71:770-2.
19. 19 Es van A, Massarano AA, Wit JM, et al. 24-Hour growth hormone secretion in Turner syndrome. In: Ranke MB, Rosenfeld R, eds. Turner syndrome: growth promoting therapies. Amsterdam: Elsevier Science Publishers, 1991: 29-33.
20. 20 Wit JM, Massarano AA, Kamp GA, et al. Growth hormone (GH) secretion in Turner girls as determined by time series analysis. Acta Endocrinol 1992;127:7-12.
21. 21 Kamp GA, Kuilboer MM, Wynne HJ, et al. Slow baseline growth and a good response to growth hormone (GH) therapy are related to elevated spontaneous GH pulse frequency in girls with Turner's syndrome. J Clin Endocrinol Metab 1993;76:1604-9.
22. 22 Smith PJ, Hindmarsh PC, Brook CGD. Contribution of dose and frequency of administration to the therapeutic effect of growth hormone. Arch Dis Child 1988;63:491-4.
23. 23 Teunenbroek van A, Muinck Keizer-Schrama de SMPF, Stijnen T, et al. Growth response and levels of growth factors after two years growth hormone treatment are similar for a once and twice daily injection regimen in girls with Turner syndrome. Clin Endocrinol 1997;46:451-9.
24. 24 Teunenbroek A, Muinck Keizer-Schrama SMPF, Stijnen T, et al. Effect of growth hormone administration frequency on 24-hour growth hormone profiles and levels of other growth related parameters in girls with Turner's syndrome. Clin Endocrinol 1993;39:77-84.
25. 25 Tanner JM. Growth at adolescence. Oxford: Blackwell Science Ltd, 1962.
26. 26 Tanner JM, Whitehouse RH, Cameron N, Marshall WA, Healy MJR, Goldstein H. Assessment of skeletal maturity and prediction of adult height (TW2-method), 2nd ed. London: Academic Press, 1983.
27. 27 Cameron N. The methods of auxological anthropometry. In: Falkner F, Tanner JM, eds. Human growth, 2, postnatal growth. London: Tindall, 1978:59-63.
28. 28 Roede MJ, Wieringen JC. Growth diagrams 1980. Netherlands third nationwide survey. Tidjschrift voor Sociale Gezondheidszorg 1985;63(suppl):1-34.
29. 29 Greulich WW, Pyle SJ. Radiographic atlas of skeletal development of the hand and wrist, 2nd ed. California: Stanford University Press, 1959.
30. 30 Bayley NB, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423-41.
31. 31 Lyon AJ, Preece MA, Grant DB. Growth curve for girls with Turner syndrome. Arch Dis Child 1985;60:932-5.
32. 32 Teunenbroek A, Stijnen T, Otten B, et al. A regression method including chronological and bone age for predicting final height in Turner syndrome, with a comparison of existing methods. Acta Paediatr 1996;85:413-20.
33. 33 Lenko HL. Prediction of adult height with various methods in Finnish children. Acta Paediatr Scand 1979;68:85-92.
34. 34 Hokken-Koelega ACS, Hackeng WHL, Stijnen T, Wit JM, Muinck Keizer-Schrama SMPF, Drop SLS. 24-Hour plasma GH profiles, urinary GH excretion and plasma TGF-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation. J Clin Endocrinol Metab 1990;71:688-95.
35. 35 Blum WF, Ranke MB, Kietzmann K, Gauggel H, Zeisel HJ, Bierich JR. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 1990;70:1292-8.
36. 36 Carlsson LMS, Rowland AM, Clark RG, Gesundheit N, Wong WLT. Ligand-mediated immunofunctional assay for quantitation of growth hormone-binding protein in human blood. J Clin Endocrinol Metab 1991;73:1216-23.
37. 37 Kratzsch J, Blum WF, Ventz M, Selisko T, Birkenmeyer G, Keller E. Growth hormone-binding protein-related immunoreactivity in the serum of patients with acromegaly is regulated inversely by growth hormone concentration. Eur J Endocrinol 1995;132:306-12.
38. 38 De Schepper J, Craen M, Massa G, et al. Growth hormone therapy in Turner's syndrome: one versus two daily injections. J Clin Endocrinol Metab 1994;79:489-94.
39. 39 Teunenbroek van A, Muinck Keizer-Schrama de SMPF, Stijnen T, Aanstoot HJ, Hoogerbrugge N, Drop SLS. Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. In: Teunenbroek van A, ed. Growth hormone treatment modalities in girls with Turner syndrome. Rotterdam: Erasmus University, 1996:147-69.
40. 40 Teunenbroek van A, Cromme-Dijkhuis AH, Muinck Keizer-Schrama de SMPF, Stijnen T, Drop SLS. Effect of long term growth hormone treatment in high dosages on left ventricular cardiac dimensions in girls with Turner syndrome. In: Teunenbroek van A, ed. Growth hormone treatment modalities in girls with Turner syndrome. Rotterdam: Erasmus University, 1996:173-87.
41. 41 Massa G, Maes M, Heinrichs C, Vandeweghe M, Craen M, Vanderschueren-Lodeweyckx M. Influences of spontaneous or induced puberty on the growth promoting effect of treatment with growth hormone in girls with Turner's syndrome. Clin Endocrinol 1993:38:253-60.
42. 42 Naeraa RW, Kastrup KW, Nielsen J. Treatment in Turner syndrome with a low dose peroral 17β-estradiol alone, or in combination with growth hormone. In: Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome. Amsterdam: Eisevier Science Publishers, 1993:209-14.